| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥283.9B | ¥292.8B | -3.0% |
| Operating Income | ¥-48.5B | ¥-14.7B | -229.6% |
| Ordinary Income | ¥-50.9B | ¥-12.6B | -305.7% |
| Net Income | ¥-95.9B | ¥-13.5B | -611.7% |
| ROE | -9.5% | -1.2% | - |
FY2026 Q3 results show Revenue of 283.9B yen (YoY -3.0%), Operating Loss of 48.5B yen (deterioration of 33.8B yen from prior year loss of 14.7B yen), Ordinary Loss of 50.9B yen (YoY -305.7%), and Net Loss of 95.9B yen (YoY -611.7%). The company maintained a gross margin of 49.8% despite revenue contraction, but substantial SG&A expenses of 189.9B yen (66.9% of revenue) and extraordinary impairment losses of 38.7B yen drove significant bottom-line deterioration. Operating cash flow remained positive at 32.6B yen despite net losses, though free cash flow recorded -154.4B yen due to large-scale investing activities of 187.1B yen. The financial position shows equity ratio of 77.7% and cash holdings of 198.3B yen, maintaining adequate liquidity despite ongoing losses.
Revenue declined modestly by 3.0% YoY to 283.9B yen, reflecting softness in core business operations. The company maintained strong gross profitability with gross profit of 141.4B yen at 49.8% margin, unchanged structurally from prior periods, indicating stable pricing power and cost of goods efficiency. However, SG&A expenses of 189.9B yen representing 66.9% of revenue created significant operating leverage challenges. Within SG&A, R&D expenses totaled 50.9B yen (17.9% of revenue), reflecting continued investment in product development despite revenue headwinds. The operating loss of 48.5B yen (operating margin of -17.1%) represents a deterioration of 33.8B yen from the prior year loss of 14.7B yen, primarily driven by the disproportionate SG&A burden relative to the revenue base.
Moving down the P&L, non-operating items contributed a net loss of 2.4B yen, comprising non-operating income of 3.1B yen (including interest income of 1.3B yen and FX gains of 0.3B yen) offset by non-operating expenses of 5.5B yen (primarily interest expense of 4.2B yen and FX losses of 0.8B yen). The ordinary loss widened to 50.9B yen from 12.6B yen in the prior year, representing a YoY deterioration of 305.7%. Extraordinary items had substantial impact with extraordinary losses of 39.7B yen dominated by impairment losses of 38.7B yen, recognized as non-recurring factors related to asset write-downs. These impairment charges, combined with a loss on disposal of assets of 0.7B yen, were partially offset by extraordinary income of 0.8B yen including gain on sale of assets of 0.3B yen.
The gap between ordinary loss of 50.9B yen and net loss of 95.9B yen totaling approximately 45.0B yen is primarily attributable to the extraordinary impairment losses of 38.7B yen and a tax expense of 6.1B yen recorded despite pre-tax losses, suggesting limitations on loss carryforward recognition or other tax adjustments. This represents a material divergence warranting investor attention to the sustainability and recurrence of earnings components.
The overall performance pattern follows a revenue down/profit down trajectory, with both top-line contraction and significant bottom-line deterioration driven by fixed cost deleverage and substantial non-recurring asset impairments.
The company operates as a single segment and does not provide segment-level breakdown for revenue or operating income.
[Profitability] Operating margin of -17.1% deteriorated substantially from prior year levels, with ROE of -9.5% reflecting net losses eroding equity returns. Gross margin remained healthy at 49.8% indicating intact pricing and production economics, but SG&A ratio of 66.9% represents unsustainable cost structure. R&D intensity of 17.9% demonstrates continued investment commitment despite profitability challenges. [Cash Quality] Cash and deposits of 198.3B yen provide 2.54x coverage of current liabilities of 78.1B yen, maintaining strong short-term liquidity. Operating cash flow of 32.6B yen represents -0.34x net income, indicating low earnings quality as losses include substantial non-cash impairment charges. [Investment Efficiency] Total asset turnover of 0.22x significantly underperforms manufacturing industry median of 0.56x, reflecting capital intensity and underutilized asset base. Inventory turnover deteriorated to 192 days versus industry median of 112 days, indicating inventory management challenges. Receivables turnover improved substantially with collection days declining as trade receivables decreased 41.7% YoY. [Financial Health] Equity ratio of 77.7% significantly exceeds industry median of 63.8%, demonstrating conservative capital structure. Current ratio of 547.4% is well above industry median of 287%, though this partly reflects operational inefficiency rather than strength. Long-term debt of 100.0B yen represents debt-to-equity of 0.10x, providing substantial debt capacity, though interest coverage is compromised by negative operating income.
Operating cash flow of 32.6B yen declined 33.1% YoY but remained positive despite net losses of 95.9B yen, with the divergence primarily driven by non-cash impairment charges of 38.7B yen and depreciation/amortization of 31.0B yen totaling approximately 69.7B yen in non-cash charges. The operating cash flow subtotal before working capital changes was 33.8B yen, with working capital providing modest support through receivables decrease of 57.5B yen (reflecting the 41.7% reduction in trade receivables) partially offset by inventory increase of 6.2B yen. Payables contributed minimal cash inflow of 0.7B yen, indicating limited supplier credit optimization. Income taxes paid were minimal at 2.5B yen reflecting loss positions, while interest and dividends received totaled 1.5B yen and interest paid was modest at 0.1B yen. Investing cash flow of -187.1B yen reflects substantial capital deployment primarily through acquisition of property, plant, equipment and intangible assets totaling approximately 123.3B yen, with construction in progress on the balance sheet increasing significantly. Financing cash flow of 61.9B yen was driven by long-term borrowing proceeds of approximately 99.5B yen, partially offset by dividend payments of 20.5B yen. Free cash flow of -154.4B yen indicates the company is consuming cash for growth investments beyond operational generation capacity, with cash and deposits declining 97.2B yen from 295.5B yen to 198.3B yen during the period.
Ordinary loss of 50.9B yen versus operating loss of 48.5B yen shows net non-operating expense of approximately 2.4B yen, representing less than 1% of revenue with primary components being interest expense of 4.2B yen partially offset by interest income of 1.3B yen and minor FX fluctuations. Non-operating items are relatively modest and recurring in nature. The substantial deterioration from ordinary loss to net loss stems from extraordinary impairment charges of 38.7B yen, which represent 13.6% of revenue and constitute clearly identifiable non-recurring factors. This one-time write-down significantly distorts bottom-line earnings quality. Operating cash flow of 32.6B yen substantially exceeds net income on an absolute basis (as net income is negative at -95.9B yen), indicating that core cash generation remains intact despite accounting losses. However, the operating CF to net income ratio of -0.34x and cash conversion ratio below industry norms signal that working capital efficiency and accruals management warrant attention. The presence of large non-cash charges improving the cash position relative to accounting earnings suggests that normalized earnings power excluding impairments would be significantly better than reported, though structural operating losses persist even excluding non-recurring items.
Progress rate versus full-year guidance stands at 67.5% for revenue (283.9B yen actual versus 421.0B yen forecast), exceeding the standard 75% Q3 benchmark by approximately 90%, though the guidance was established for the full year rather than nine-month basis. Operating loss progress is 121.4% of full-year forecast (48.5B yen loss versus 40.0B yen forecasted loss), indicating worse-than-expected operating performance requiring potential downward revision or Q4 recovery. Ordinary loss of 50.9B yen represents 115.7% of forecasted 44.0B yen loss, similarly running ahead of expected loss levels. Net loss of 95.9B yen has reached 106.6% of the 90.0B yen forecasted full-year loss, largely due to the Q3 impairment charges. The company has not revised forecasts this quarter despite Q3 results suggesting full-year operating and ordinary losses may exceed guidance. Forecast assumptions note that projections are based on currently available information and involve uncertainties, with reference to page 2 of supplementary materials for details on forward-looking assumptions, though specific drivers such as product pipeline timing, cost reduction initiatives, or market assumptions are not quantified in available disclosures.
Annual dividend of 17.0 yen per share was declared for the fiscal year-end, compared to prior year information suggesting a resumption or initiation of dividends. Payout ratio relative to net loss of 95.9B yen is not meaningful as it results in negative coverage of approximately -21.3%, indicating dividends are paid from retained earnings rather than current period profits. Total dividend payment of approximately 20.5B yen as shown in financing cash flows represents 62.8% of operating cash flow of 32.6B yen, which is supportable from operational cash generation despite accounting losses. However, free cash flow of -154.4B yen implies dividends are funded by debt financing rather than free cash generation, with dividend coverage from FCF at approximately -7.5x indicating unsustainability at current investment levels. No share buyback activity was disclosed. The total return ratio incorporating only dividends against net income is not calculable given negative earnings, and the decision to maintain shareholder returns during loss periods reflects either confidence in near-term recovery or commitment to shareholder relations despite financial challenges.
Asset impairment risk remains elevated with goodwill of 120.6B yen and intangible assets of 240.0B yen totaling 360.6B yen or 27.6% of total assets, following impairment charges of 38.7B yen in the current period. Further deterioration in business conditions or investment returns could trigger additional write-downs materially impacting equity of 1,013.3B yen. Working capital inefficiency poses cash consumption risk with inventory days of 192 days significantly exceeding industry median of 112 days, representing approximately 75.0B yen in finished goods, raw materials and work in process. Prolonged inventory turnover increases obsolescence risk and ties up cash that could otherwise reduce debt or fund operations. Cost structure sustainability represents a critical risk with SG&A expenses of 189.9B yen exceeding gross profit of 141.4B yen by 48.5B yen, creating structural operating losses. Without revenue growth exceeding 34% or SG&A reduction of 25%, the company cannot achieve operating profitability, and R&D expenses of 50.9B yen embedded in SG&A limit flexibility to cut costs without compromising long-term competitiveness.
[Industry Position] (Reference - Proprietary Analysis)
The company's financial metrics show significant divergence from manufacturing industry medians across multiple dimensions. Profitability metrics underperform substantially with operating margin of -17.1% versus industry median of +8.9% and ROE of -9.5% versus industry median of +5.8%, placing the company well below the 25th percentile for profitability. Net profit margin of -33.8% compares unfavorably to industry median of +6.5%, though this is heavily influenced by non-recurring impairment charges. Excluding extraordinary items, normalized operating performance still trails industry standards due to elevated SG&A burden.
Financial health metrics present a mixed picture with equity ratio of 77.7% substantially exceeding industry median of 63.8%, indicating conservative leverage and strong solvency positioning above the 75th percentile. Current ratio of 547.4% far exceeds industry median of 287%, though this partially reflects operational inefficiency rather than superior liquidity management. The company maintains net cash position with minimal debt relative to market cap, contrasting with industry median net debt to EBITDA of -1.11x.
Efficiency metrics reveal significant underperformance with asset turnover of 0.22x substantially below industry median of 0.56x, indicating capital intensity and underutilization placing the company in the bottom quartile. Inventory turnover of 192 days exceeds industry median of 112 days by 71%, reflecting working capital management challenges. However, payables turnover improved with reduced receivables partially offsetting inventory inefficiency.
Growth and cash generation metrics show revenue decline of -3.0% versus industry median growth of +2.8%, placing the company in the bottom half of peers. Operating cash flow remains positive but free cash flow yield is deeply negative due to large-scale capital investments, contrasting with industry median FCF yield of +2%.
The company's positioning reflects a capital-intensive biotechnology manufacturer undergoing significant investment phase with temporarily depressed profitability but maintaining strong balance sheet capacity to fund transformation.
(※ Industry: Manufacturing (N=105 companies for most metrics), Comparison period: 2025-Q3 industry medians, Source: Proprietary analysis)
Key Takeaways from Earnings reveal three significant structural characteristics. First, the company maintains differentiated gross margin of 49.8% indicating strong product value proposition and pricing power, but faces substantial operating leverage challenges with SG&A ratio of 66.9% creating structural operating losses requiring either significant revenue scale expansion or cost restructuring for profitability restoration. Second, large-scale capital investment program evidenced by investing cash flow of -187.1B yen and increases in construction in progress and intangible assets totaling 160.3B yen suggests major facility expansion or technology platform buildout, representing a strategic inflection point where near-term cash consumption and losses are trading off against future capacity and revenue potential, with investment returns becoming measurable in subsequent periods. Third, balance sheet strength with equity ratio of 77.7% and cash reserves of 198.3B yen provides substantial financial flexibility to sustain the current investment program and operational losses for multiple periods, with long-term debt of only 100.0B yen offering significant additional debt capacity if required, though management's willingness to maintain dividends of 20.5B yen during loss periods signals confidence in stabilization trajectory, albeit at risk of capital allocation inefficiency if investments fail to generate expected returns.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.